Managing Ventricular Arrhythmias in LVAD Patients

Ventricular arrhythmias are frequent and clinically important in people supported by a left ventricular assist device (LVAD). Sustained ventricular tachycardia (VT), ventricular fibrillation (VF), and recurrent implantable cardioverter-defibrillator (ICD) therapies may occur before implantation, during the early postoperative period, or months later. The mechanical pump can maintain systemic flow during an episode, but it does not remove the risk of right ventricular failure, thromboembolism, myocardial injury, or death.

Management therefore requires more than terminating the rhythm. Clinicians must identify reversible triggers, assess pump function, protect the right ventricle, reduce shocks, and decide whether catheter ablation, device reprogramming, medication, or transplantation should be pursued. In Australia, this work commonly involves collaboration between LVAD programmes, electrophysiology services, intensive care teams, retrieval networks, and community hospitals that may have limited experience with durable mechanical circulatory support.

Why Ventricular Arrhythmias Develop

The substrate is often present before LVAD implantation. Ischaemic scar, non-ischaemic cardiomyopathy, ventricular dilation, fibrosis, and previous myocarditis can support monomorphic VT or polymorphic ventricular arrhythmias. Surgical trauma and cannula placement may create additional areas of slow conduction. The inflow cannula, apical scar, and border zones around the ventriculotomy can become relevant targets when arrhythmias persist after support begins.

Haemodynamic unloading changes ventricular geometry and autonomic balance. Reduced left ventricular filling can increase suction events, while septal shift may worsen right ventricular performance. Electrolyte depletion, hypoxaemia, acidosis, infection, fever, anaemia, and catecholamine exposure can lower the threshold for VT or VF. Medication changes also matter: withdrawal of beta-blockade, pro-arrhythmic drug interactions, and excessive diuresis may all contribute.

An arrhythmia that appears “tolerated” because the LVAD continues to generate flow still requires urgent evaluation. Pulsatility may fall, alarms may sound, and the patient can develop syncope or end-organ hypoperfusion even when a palpable pulse is absent or difficult to detect. The rhythm, pump parameters, echocardiographic findings, and clinical perfusion must be interpreted together.

Initial Assessment And Emergency Care

The first response follows advanced life support principles while recognising the altered physiology of continuous-flow support. An unresponsive patient with no signs of perfusion should receive immediate defibrillation and cardiopulmonary resuscitation according to local protocol. Modern LVAD systems are designed to tolerate external defibrillation, although pads should be positioned to avoid the pump and driveline where practical. The specialist LVAD coordinator or on-call centre should be contacted early.

In a conscious patient, obtain a 12-lead ECG, assess mental status and peripheral perfusion, and review the device controller, alarms, speed, power, flow estimate, and pulsatility index. These displayed values are not direct measurements of cardiac output, and an apparently stable pump reading does not exclude arrhythmia or right-sided failure. Point-of-care ultrasound can help assess ventricular size, septal position, pericardial fluid, and gross pump inflow, while formal echocardiography may be needed.

Immediate laboratory testing should include potassium, magnesium, calcium, renal function, acid-base status, troponin, full blood count, and markers of infection when indicated. The team should check for hypovolaemia, bleeding, tamponade, pump thrombosis, inflow or outflow obstruction, and acute coronary syndrome. In Australian practice, a patient presenting to a regional emergency department may need early coordination with a metropolitan LVAD centre in Melbourne, Sydney, Brisbane, or another state-based referral hub before transfer decisions are made.

For device-specific background and clinical literature, clinicians can consult the journal’s arrhythmia articles alongside manufacturer guidance and the patient’s centre protocol. Published evidence is valuable, but emergency decisions should remain individualised and should not be delayed while searching for an exact precedent.

Optimising The LVAD And The Right Ventricle

Pump settings should be reviewed when arrhythmia begins or becomes recurrent. Excessive speed can reduce left ventricular volume, promote suction, and aggravate ventricular ectopy or VT. Inadequate unloading can leave a distended ventricle with increased wall stress and persistent arrhythmogenic substrate. Speed changes should be made by the LVAD team, generally with echocardiographic and haemodynamic assessment rather than relying on a single displayed parameter.

Right ventricular function is central to successful management. The right ventricle must deliver blood through the pulmonary circulation to the LVAD. Sustained VT reduces right ventricular output, which then lowers LVAD preload and may produce low-flow alarms. Treating congestion, correcting hypoxia and acidosis, and using carefully selected inotropes or pulmonary vasodilators may be necessary. Excessive volume loading can worsen right-sided congestion, while aggressive diuresis can precipitate suction.

Recurrent ventricular arrhythmia should prompt a search for mechanical and structural causes. Echocardiography may identify a poorly positioned inflow cannula, septal shift, severe mitral regurgitation, or new right ventricular dysfunction. Computed tomography angiography can be useful when outflow graft obstruction is suspected, although renal function and haemodynamic stability must be considered. Pump thrombosis requires a separate diagnostic and anticoagulation strategy and should not be assumed solely because power consumption rises.

Medication And ICD Strategies

Beta-blockers remain important when blood pressure and right ventricular function permit. Amiodarone is commonly used for recurrent VT, but long-term exposure brings thyroid, hepatic, pulmonary, ocular, and drug-interaction concerns. Lidocaine may be useful during an acute electrical storm, while mexiletine is sometimes added for refractory ventricular arrhythmia. Renal and hepatic function, QT interval, anticoagulation, and transplant plans should influence drug selection.

Electrolyte replacement is a simple but high-value intervention. Many centres aim for high-normal potassium and magnesium concentrations in patients with recurrent VT, while avoiding unsafe supplementation in renal failure. Medication reconciliation should include diuretics, antibiotics, antidepressants, antiemetics, and other drugs that can prolong repolarisation or alter antiarrhythmic concentrations.

Most durable LVAD recipients have an ICD for secondary prevention or primary prevention according to their underlying cardiomyopathy and expected benefit. Programming should minimise unnecessary shocks while retaining protection from VF and haemodynamically dangerous VT. Antitachycardia pacing, longer detection intervals, higher rate cut-offs, and discriminators can reduce therapies in selected patients. The balance changes if VT causes low flow, syncope, or rapid right ventricular deterioration.

An electrical storm requires sedation, sympathetic suppression, correction of triggers, and urgent electrophysiology involvement. Repeated shocks can amplify catecholamine release and worsen the cycle. Magnet use, temporary device therapy suspension, and reprogramming should be performed only by clinicians familiar with the ICD and LVAD combination, with external defibrillation immediately available.

Catheter Ablation In Selected Patients

Catheter ablation should be considered for incessant VT, recurrent ICD shocks, medication intolerance, or a clinical pattern that threatens LVAD function. It may also be appropriate before transplantation when arrhythmia is likely to compromise candidacy or rehabilitation. In some patients, ablation reduces hospitalisation and shock burden even when it does not eliminate every inducible rhythm.

The procedure can be technically complex. Mapping may require transseptal access, retrograde aortic access, epicardial assessment, or specialised strategies around the apical cannula. Intracardiac echocardiography and three-dimensional mapping help define scar and avoid cannula-related injury. The operator must account for anticoagulation, vascular access, bleeding risk, device location, and the possibility of haemodynamic collapse during induced VT.

Epicardial ablation may be limited by prior surgery, adhesions, and the risk of bleeding in an anticoagulated patient. A multidisciplinary decision involving electrophysiology, advanced heart failure, cardiac surgery, anaesthesia, and imaging is essential. Procedural planning should specify pump speed management, anticoagulation interruption or continuation, rescue mechanical support, and postoperative monitoring.

Evidence remains predominantly observational, with outcomes influenced by the arrhythmia mechanism and timing after implant. Early postoperative VT may resolve as inflammation and loading conditions improve, whereas late monomorphic VT often reflects fixed scar. This distinction helps determine whether immediate ablation or a period of medical and device optimisation is more appropriate.

Long-Term Planning And Australian Practice

Ventricular arrhythmia is a marker of advanced myocardial disease, but its meaning varies. Some patients recover after a reversible trigger is treated; others have progressive right ventricular failure, recurrent admissions, or increasing dependence on antiarrhythmic therapy. Follow-up should include ICD interrogation, LVAD parameters, echocardiography, renal and hepatic monitoring, anticoagulation review, functional status, and assessment of psychological effects from shocks.

Patients and carers need a practical emergency plan. It should explain when to call emergency services, how to identify alarms, what equipment to bring, and which LVAD centre to contact. Travel planning is particularly relevant in Australia, where distances between metropolitan transplant services and rural or remote communities can be substantial. The patient should carry device identification, controller and battery information, medication details, and the centre’s 24-hour contact number.

Local systems must account for ambulance familiarity with durable LVADs and the availability of electrophysiology expertise outside major hospitals. The Alfred in Melbourne, St Vincent’s Hospital in Sydney, and the Queensland cardiac network are examples of metropolitan services involved in advanced heart failure and mechanical support; referral pathways vary by state and patient location. In Western Australia, South Australia, Tasmania, and the Northern Territory, retrieval coordination may be especially important when a patient presents far from the implanting centre.

The Australian device market also shapes care. HeartMate 3 is widely used in contemporary durable support, while older devices and legacy controllers may still be encountered. Clinicians should verify the exact pump model, controller generation, battery type, and manufacturer instructions rather than applying assumptions from another system. Local availability of consumables, remote monitoring, and specialist review should be incorporated into discharge and outreach planning.

Research Priorities And Multidisciplinary Care

Future studies should distinguish ventricular arrhythmias by timing, mechanism, device type, and haemodynamic effect. Registry work can clarify whether early postoperative episodes carry the same prognostic significance as late scar-mediated VT. Better data are also needed on ablation timing, ICD programming, autonomic modulation, wearable monitoring, and the interaction between arrhythmia treatment and transplant eligibility.

Research from Asia-Pacific populations is particularly relevant to clinicians working across different healthcare systems, distances, and device access models. The journal’s special issues provide a useful route to themed collections covering electrophysiology, mechanical circulatory support, ablation, and related areas. Clinicians should interpret emerging findings alongside local governance requirements, institutional expertise, and the patient’s goals of care.

A coordinated team remains the strongest management strategy. Electrophysiologists can define the rhythm and programme the ICD; heart failure specialists can optimise preload, afterload, and right-sided function; surgeons and imaging specialists can assess mechanical complications; pharmacists can manage interactions; and nurses can support education and continuity. Palliative care may also help when recurrent shocks, progressive organ failure, or limited treatment options affect quality of life.

For clinicians developing protocols, audit should track time to specialist review, inappropriate shocks, VT recurrence, ablation outcomes, emergency transfers, and patient-reported distress. Questions about LVAD arrhythmia care, submissions, and journal activities can be directed through the publication’s contact information. Sharing carefully documented Australian experience can strengthen practice across the region.

A safe, effective pathway links rapid rhythm termination with systematic investigation of pump function, ventricular loading, reversible triggers, and long-term goals. Build that pathway into local emergency guidelines, educate ambulance and hospital teams, and review every recurrent episode through a multidisciplinary LVAD and electrophysiology meeting. Use current evidence, device-specific instructions, and structured follow-up to reduce shocks while preserving perfusion, mobility, and access to advanced heart failure therapies.